Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes. DATA SOURCES: English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015). STUDY SELECTION: Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations. DATA EXTRACTION: Two reviewers independently assessed study quality and serially extracted data and graded the strength of evidence. DATA SYNTHESIS: Cardiovascular mortality was lower for metformin versus sulfonylureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complications was insufficient or of low strength. Reductions in hemoglobin A1c values were similar across monotherapies and metformin-based combinations, except that DPP-4 inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thiazolidinediones, and insulin (between-group differences up to 5 kg). Hypoglycemia was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1 receptor agonists. Genital mycotic infections were increased with SGLT-2 inhibitors. LIMITATION: Most studies were short, with limited ability to assess rare safety and long-term clinical outcomes. CONCLUSION: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compounds that modulate NF-κB signalling, including metformin137,235–237, apigenin238, kaempferol238 and BAY 11–7082 (REF.118), have also been shown to decrease SASP production.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [236]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We evaluated the heterogeneity among the trials by using the I(2) statistic (11).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We generated summary treatment effects with the random-effects model estimated by using the DerSimonian and Laird method in settings of low heterogeneity (I(2) < 50%) (12) and the profile likelihood estimate in settings of high heterogeneity (I(2) ≥ 50%) (13).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Two independent reviewers assessed risk of bias in individual RCTs by using the criteria of Jadad and colleagues (9), as in our prior review (6).”
MethodDowns, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used the Downs and Black tool for assessment of the risk of bias for the nonrandomized trials and observational studies (10).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 1
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2
Cited by
Items 401–500 of 733
Westhoff, M. S., Schröder, S., Groh, A., Frieling, H., Bleich, S., Koop, F., Stichtenoth, D. O., Krichevsky, B., & Heck, J. (2023) · Psychogeriatrics · doi:10.1111/psyg.12940 · Cited by 7
Sakellariou, X. M., Kolettis, T. M., & Nikas, D. N. (2023) · Clinical Medicine & Research · doi:10.3121/cmr.2022.1759 · Cited by 7
Xie, T., & Zhao, L.-J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116343 · Cited by 7
CE: Type 2 Diabetes: A Pharmacologic Update
Keresztes, P. A., & Peacock-Johnson, A. (2019) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000554008.77013.cf · Cited by 8
Sánchez, R. I., Yee, K. L., Li, F., Cislak, D., Martell, M., Jordan, H. R., Iwamoto, M., & Khalilieh, S. G. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.685 · Cited by 8
Gholami, A., Bahrami, F., & Faraji, M. (2020) · PubMed Central · doi:10.22037/ijpr.2019.111659.13292 · Cited by 7
Impact of metformin on the therapeutic effect of radiotherapy
Agbele, A. T., Faromika, O. P., Awe, O. O., Amodu, F. R., Edaogbogun, G. O., & Bello, K. A. (2020) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2020.12.002 · Cited by 8
Federici, M. O., Gentilella, R., Corcos, A., Torre, E., & Genovese, S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3434 · Cited by 8
Kim, H., Bae, S., Yoon, H. Y., Yee, J., & Gwak, H. S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac333 · Cited by 7
Xhakaza, L., Abrahams-October, Z., Pearce, B., Masilela, C. M., Adeniyi, O. V., Johnson, R., Ongole, J. J., & Benjeddou, M. (2020) · Drug metabolism and drug interactions · doi:10.1515/dmpt-2020-0111 · Cited by 7
Mendonça, I. R., Rosendo, A. B., da Silva, B. B., & Iser, B. P. M. (2023) · DEMETRA Alimentação Nutrição & Saúde · doi:10.12957/demetra.2023.70199 · Cited by 12
Optimal individualized treatment rule for combination treatments under budget constraints
Xu, Q., Fu, H., & Qu, A. (2023) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1093/jrsssb/qkad141 · Cited by 11
“…able to reduce treatment failure or fatality rates, and overcome treatment resistance for many chronic diseases (e.g., Mokhtari et al., 2017; Kalra et al., 2010; Maruthur et al., 2016; Bozic et al., 2013; Korkut et al., 2015; M¨ott¨onen et al., 1999; Forrest and Tamura, 2010; Tamma et al., 2012).”
BackgroundWilkinson, S., Tomlinson, L. A., Iwagami, M., Stirnadel-Farrant, H. A., Smeeth, L. L., & Douglas, I. (2018) · Wellcome Open Research · doi:10.12688/wellcomeopenres.14660.1 · Cited by 7
Sagrillo‐Fagundes, L., Bienvenue‐Pariseault, J., Legembre, P., & Vaillancourt, C. (2019) · Birth Defects Research · doi:10.1002/bdr2.1470 · Cited by 8
Kamalinia, S., Josse, R. G., Donio, P. J., Leduc, L., Shah, B. R., & Tobe, S. W. (2019) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.100 · Cited by 7
The effect of metformin on the risk of recurrent nonmelanoma skin cancers
Ravishankar, A., Zhang, T., Lindgren, B. R., Farah, R. S., Dong, Z., & Goldfarb, N. I. (2020) · International Journal of Dermatology · doi:10.1111/ijd.14829 · Cited by 7
Garcia-Hernandez, S. C., Porchia, L. M., Pacheco-Soto, B. T., López‐Bayghen, E., & González-Mejía, M. E. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1913114 · Cited by 8
“Metformin has shown promise in Type 2 diabetics to reduce IR [10] and several studies demonstrated its effect to improve metabolic, endocrine, and reproduction abnormalities in PCOS women [11–13].”
BackgroundGlucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Inzucchi, S. E., Peixoto, A. J., & Testani, J. M. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107340 · Cited by 7
Metformin: An Old Drug with New Tricks—Promising Role in Vascular Aging and Cardioprotection
Sivakumar, R., Senghor, K. A. A., Vinodhini, V. M., & Kumar, J. S. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01215-3 · Cited by 7
Hui, J. M. H., Zhou, J., Lee, T. T. L., Hui, K., Chou, O. H. I., Lee, Y. H. A., Lee, S., Wong, W. T., Wai, A. K. C., Chang, C., et al. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104086 · Cited by 7
Maya, S. A., Shumon, M. A. H., Islam, M. R., Khan, J. M., Khan, S. A., Rana, S., Hoque, M. A., & Rahman, M. M. (2024) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2024.101295 · Cited by 6
Li, Y., Xu, Q., Wang, J., Xin, Y., Zhang, Y., Qin, X., Xu, K., Yang, X., & Wang, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c07282 · Cited by 7
Inagaki, N., Nishimoto, T., Nishiya, Y., & Nitta, D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2107200 · Cited by 7
Mishra, A. P., Nigam, M., Nambooze, J., Salau, V. F., Olofinsan, K. A., Iriti, M., & Matsabisa, M. G. (2023) · Current Organic Chemistry · doi:10.2174/0113852728254495231002100354 · Cited by 6
Liang, Y.-C., Li, L., Liang, J.-L., Liu, D., Chu, S.-F., & Li, H.-L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1403943 · Cited by 6
Zaghloul, A.-A. A., Lila, A., Abd-Allah, F. I., & Nada, A. H. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1280810 · Cited by 6
Zhang, Y., Yu, X., Zhu, J., Liu, S., Liu, X., Dong, Q.-X., Chai, J.-Q., & Liu, R. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.11.012 · Cited by 6
Avogaro, A., Barillà, F., Cavalot, F. L., Consoli, A., Federici, M., Mancone, M., Paolillo, S., Pedrinelli, R., Perseghin, G., Filardi, P. P., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.029 · Cited by 6
Glucose-lowering therapy in patients undergoing percutaneous coronary intervention
Johansson, I., Dicembrini, I., Mannucci, E., & Cosentino, F. (2021) · EuroIntervention · doi:10.4244/eij-d-20-01250 · Cited by 8
Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
Singh, A. K., & Singh, R. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i6.466 · Cited by 6
Khan, R. A., Patel, N., Folajimi, A., Bansari, R. B., Patel, V., Komminni, P. K., Palleti, S. K., & Hirani, S. (2023) · Cureus · doi:10.7759/cureus.35014 · Cited by 11
“A previous review focused on adult populations and showed that results for add-on therapies to metformin were similar to those for monotherapies [11].”
ResultConsenso ALAD. Tratamiento del paciente con diabetes mellitus tipo 2 y obesidad
BRAJKOVICH, I. E., Aschner, P. J., Taboada, L. B., Camperos, P., Gómez‐Pérez, R., Aure, G., Velásquez, M. E., Halpern, B., Jiménez, M. C. H., & Fuentes, O. (2019) · Alad · doi:10.24875/alad.19000369 · Cited by 11
A Summary of the Fifth Annual Virology Education HIV Microbiome Workshop
Sherrill-Mix, S. A., Connors, K. A., Aldrovandi, G. M., Brenchley, J. M., Boucher, C. A., Bushman, F. D., Collman, R. G., Dandekar, S., Klatt, N. R., Lagenaur, L. A., et al. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2020.0121 · Cited by 6
Ostroumova, O. D., Surkova, E. V., Васильевна, Г. И., Starodubova, A. V., Кочетков, А. И., Kiknadze, T. D., & Galstyan, G. R. (2020) · Diabetes Mellitus · doi:10.14341/dm10202 · Cited by 6
Nicholas, S. B., & Tuttle, K. R. (2020) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2020.19.2.5 · Cited by 6
Robeson, M. S., Manna, K., Randolph, C., Byrum, S. D., & Hakkak, R. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.834776 · Cited by 6
“Metformin is primarily administered alone or in combination with other hypoglycemic drugs to effectively control the blood glucose level of diabetic individuals, particularly to obese or overweight patients (Maruthur et al., 2016; Thomas and Gregg, 2017).”
BackgroundGuo, L., Chen, L., Chang, B., Yang, L., Liu, Y., & Feng, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13454 · Cited by 6
“Metformin has many benefits; it reduces glycated haemoglobin (HbA1c) by 1%2%,(5) and the antihyperglycaemic effects of metformin monotherapy are comparable to those obtained with sulfonylureas and thiazolidinediones.(6,7) Chronic metformin treatment is associated with low risks of weight increase and hypoglycaemia.”
ResultGlucagon-like peptide-1 receptor agonists and risk of breast cancer
Bolen, S. D., & Maruthur, N. M. (2016) · BMJ · doi:10.1136/bmj.i5519 · Cited by 6
Self-citationEfficacy and Cardiovascular Safety of Antidiabetic Medications
Pappachan, J. M. (2021) · Current Drug Safety · doi:10.2174/1574886316666210112153429 · Cited by 6
“8 kg, depending on the drug molecule in the subclass used [27-30].”
BackgroundRecent Advances in Electrically Stimulated Insulin Delivery Systems
Alemán, C., Muñoz-Galán, H., & Pérez‐Madrigal, M. M. (2025) · ACS Omega · doi:10.1021/acsomega.5c06147 · Cited by 5
Recent synthetic strategies using MCRs for the discovery of pharmacologically active compounds
Sakthivel, K., & Singh, F. V. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2617611 · Cited by 7
Yan, Y., Luo, Z., Deng, T., Cui, X., Juan, Y., Pan, X., Yang, L., Wang, Y., Li, L., Li, L., et al. (2022) · Food Science and Technology · doi:10.1590/fst.41822 · Cited by 5
Maya, S. A., Khan, J. M., Islam, M. R., Shumon, M. A. H., Banjare, M. K., Rana, S., & Hoque, M. A. (2024) · Molecular Physics · doi:10.1080/00268976.2024.2349195 · Cited by 5
Aladenika, Y. V., Akinjiyan, M. O., Elekofehinti, O. O., & Adanlawo, I. G. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119116 · Cited by 5
Abdalla, M. A., Shah, N. Z., Deshmukh, H., Sahebkar, A., Östlundh, L., Al‐Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2021) · Clinical Endocrinology · doi:10.1111/cen.14663 · Cited by 5
“A recent systematic review and meta‐ analysis evaluating the efficacy of different pharmacological interventions on adults with T2DM showed that body weight was either significantly reduced or maintained in treatment with metformin and DPP‐4 inhibitors.(110) Another meta‐analysis of 15 RCTs evaluating the effects of p…”
BackgroundStructural insights and supramolecular description of Gliclazide and its Impurity F
Santos, M. O., Borges, I. D., Santin, L. G., Oliveira, S. S., Rosseto, L. P., Sallum, L. O., Camargo, A. J., Fajemiroye, J. O., Perjési, P., & Napolitano, H. B. (2022) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2022.113707 · Cited by 5
Okada, M., Bando, H., Iwatsuki, N., Sakamoto, K., & Ogawa, T. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6303 · Cited by 5
Boutsikos, I., Beltsios, E. T., Schmack, B., Pantazopoulos, I. N., & Chatzis, D. (2023) · Heart International · doi:10.17925/hi.2023.17.2.12 · Cited by 5
Nutritional and health promoting perspectives of Monostroma spp. (Chlorophyta): A systematic review
Mansoor, S., Bashir, K. M. I., Mohibbullah, M., Meinita, M. D. N., Khan, M. N. A., Sohn, J. H., & Choi, J. (2024) · Journal of Applied Phycology · doi:10.1007/s10811-023-03176-9 · Cited by 5
Xu, S., Zheng, B., Su, B., Finkelstein, S. N., Welsch, R. E., Ng, K., & Shahn, Z. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae217 · Cited by 6
Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo
Lee, K. H., Lee, S. D., Kim, N., Suh, K. H., Kim, Y., & Sim, S. S. (2019) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2019.23.1.55 · Cited by 5
Macalalad-Josue, A. A., Palileo‐Villanueva, L. M., Sandoval, M. A., & Panuda, J. P. (2019) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.034.01.08 · Cited by 6
Campbell, S. A., Light, P. E., & Simpson, S. H. (2019) · Diabetic Medicine · doi:10.1111/dme.14154 · Cited by 5
Dorati, C., Buschiazzo, P. M., Marin, G. H., Buschiazzo, H., Rojas-Cortés, R., Arvez, M. J. A., Cardozo, J. M., Marín, D., de Hernández, G. I. H., Maldonado, N. L., et al. (2021) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2021.152 · Cited by 5
“Estos indicadores se seleccionaron con base en su uso en experiencias previas (8, 9) y evidencias de beneficio-riesgo de los respectivos medicamentos, inclusive una disminución de la mortalidad con el empleo de metformina (20-27).”
BackgroundAl-Waeli, D. K., Mohammed, A. G., Tahir, I. H., Al-Saeedi, A. K. S., Razzaq, K. H., & Abodhurais, A. (2022) · Journal of Medicine and Life · doi:10.25122/jml-2021-0259 · Cited by 5
“Furthermore, it has a beneficial effect on weight reduction and may be associated with less cardiovascular morbidity and mortality [8, 9].”
BackgroundAn Unusual Association Between Metformin and Nightmares: A Case Report
Voloshyna, D., Sandhu, Q. I., Khan, S., Bseiso, A., Mengar, J., Nayudu, N., Kumar, R., Khemani, D., & Usama, M. (2022) · Cureus · doi:10.7759/cureus.28974 · Cited by 5
“Hypoglycemia is uncommon in patients on metformin monotherapy, but Sulfonylureas carry a larger risk of hypoglycemia [2, 9].”
BackgroundHakim, M. A., Sanni, A., Osman, S. T., Hamdy, N. A., Purba, W. T., Bhuiyan, M. M. A. A., Onigbinde, S. B., El-Khordagui, L. K., EL‐Yazbi, A. F., & Mechref, Y. S. (2025) · PROTEOMICS · doi:10.1002/pmic.70000 · Cited by 4
“However, patient responses to treatment can vary significantly, underscoring the need for a personalized medicine approach that combines metformin with other antidiabetic drugs for optimal therapeutic outcomes [38, 39].”
Ono, R., Ogami, C., Hasegawa, C., To, H., Matsumoto, Y., & Tsuji, Y. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00716-4 · Cited by 4
Longo, M., Caruso, P., Scappaticcio, L., Maiorino, M. I., Bellastella, G., Capuano, A., Esposito, K., & Giugliano, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15451 · Cited by 4
Chiu, C., Chiu, Y.-P., Yip, H., Ji, H.-R., Cho, D., Cheng, I. H.-J., & Chen, C.-Y. (2024) · Neuroepidemiology · doi:10.1159/000539001 · Cited by 4
Lugo-Palacios, D. G., Bidulka, P., O’Neill, S., Carroll, O., Basu, A., Adler, A., Diaz‐Ordaz, K., Briggs, A. H., & Grieve, R. (2024) · Health Economics · doi:10.1002/hec.4903 · Cited by 4
Bie, N., Li, S., Liang, Q., Zheng, W., Xu, S., Liu, H., Zhang, X., Wei, Z., Yong, T., Yang, X., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00709 · Cited by 4
Saadh, M. J., Gataa, I. S., Hussam, A. S., Kaur, I., Kumar, A., Godara, P., Zainul, R., Muzammil, K., & Zahrani, Y. I. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2025.07.015 · Cited by 4
OKADA, M., Bando, H., Iwatsuki, N., Sakamoto, K., & Ogawa, T. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6284 · Cited by 4
Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy
Bando, H., Yamashita, H., Kato, Y., OGURA, K., & Kato, Y. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6293 · Cited by 4
Yu, G., Sun, M., Zhang, T., Xu, H., Wang, J., Ye, W., Wang, P., Zhang, S., Zhang, C., & Sun, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117248 · Cited by 4
Tiwari, R. K., Ahmad, A., Chadha, M., Saha, K., Verma, H., Borgohain, K., & Shukla, R. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998294919240506044544 · Cited by 5
A potent free fatty acid receptor 1 agonist with a glucose-dependent antihyperglycemic effect
Wang, X., Xu, Y., Feng, S., Huang, X., Meng, X., Chen, J., Guo, L., Ge, J., Zhang, J., Chen, J., et al. (2019) · Chemical Communications · doi:10.1039/c9cc04040d · Cited by 4
Xhakaza, L., Abrahams-October, Z., Pearce, B., Masilela, C. M., Adeniyi, O. V., Johnson, R., Ongole, J. J., & Benjeddou, M. (2020) · Drug Metabolism and Personalized Therapy · doi:10.1515/dmdi-2020-0111 · Cited by 6
Dubayee, M. A., Alshahrani, A. S., Aljada, D., Zhra, M., Alotaibi, A., Ababtain, I., Alnaim, M., Alahmari, A. M., Aljarallah, A., Elahi, M. A., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s300048 · Cited by 4
“Several reports demonstrated the cardioprotective effects of metformin.(51,52) Metformin inhibits NF-κB pathway in vascular wall cells and experimental atherogenesis of rabbits.”
BackgroundWu, C., Tsai, Y., Jung, H.-K., Fu, S., Hsiung, C. A., Liu, H., & Lai, J. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1965 · Cited by 5
Liu, G., Huang, Z., & Qian, X. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9972386 · Cited by 4
Arnold, S. V., McGuire, D. K., Inzucchi, S. E., Tang, F., Mehta, S. N., Lam, C. S. P., Goyal, A., Sperling, L. S., Wong, N. D., Hammar, N., et al. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.02.009 · Cited by 4
Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice
Ermini, G., Tosetti, C., Zocchi, D., Mandreoli, M., Caletti, M. T., & Marchesini, G. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0983-0 · Cited by 4
Metformin and Infections: What Is the Next Step in This Decades-Long Story?
Goto, M., & Perencevich, E. N. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac903 · Cited by 4
Nardi, E., Prastaro, M., Santoro, C., Gallo, L., Simeoli, L., Fontanarosa, S., Paolillo, S., Gargiulo, P., Esposito, G., & Filardi, P. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104033 · Cited by 3
Wang, X., Chen, X., Feng, R., Jiang, H., & Liu, W. (2025) · International Journal of COPD · doi:10.2147/copd.s516346 · Cited by 3
Fériz, K., Rincón, A. R., Tovar, H., Restrepo-Erazo, K., Yepes, C. A., Brito, E. M., Gómez, N. B., Amézquita, Y. C. H., Iriarte-Durán, M. B., Jimenez, L., et al. (2025) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.12.3.907 · Cited by 3
Qu, Y., Wang, Y., Zhang, Y., Wu, H., & Yao, Y. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02825-3 · Cited by 3
Lin, J., Yang, R., Zhuang, J., Zhang, W., Tong, Q., Liu, J., Kang, Y., & Yuan, Y. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02078-x · Cited by 3
azhir, S., Alijani, E., Martínez-Huenchullán, S., Amni, H., Baker, J., & Farhani, F. (2022) · Retos · doi:10.47197/retos.v44i0.91770 · Cited by 4
Shareef, M. A., Sofy, A. A., Abdelsattar, A. T., Masoud, A. T., Farhat, A. M., & Maarouf, H. (2022) · Journal of Turkish Society of Obstetric and Gynecology · doi:10.4274/tjod.galenos.2022.26257 · Cited by 3
Fan, Y., Cai, Q., Chen, S., Zhang, B., Zhang, Y., Zhen, J., & Zhang, G. (2023) · European Radiology · doi:10.1007/s00330-023-09611-2 · Cited by 3
Dahlquist, A., Jandali, D., Nauman, M. C., & Johnson, J. J. (2023) · International Journal Of Nutrition · doi:10.14302/issn.2379-7835.ijn-23-4737 · Cited by 3
Basu, A., Montano‐Campos, F., Huang, E. S., Laiteerapong, N., & Barthold, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15878 · Cited by 3
Elekofehinti, O. O., Molehin, O. R., Akinjiyan, M. O., & Fakayode, A. E. (2024) · Journal of Food Bioactives · doi:10.26599/jfb.2024.95027390 · Cited by 3
Carroll, O., Bidulka, P., Basu, A., Adler, A., O’Neill, S., Briggs, A. H., Lugo-Palacios, D. G., Khunti, K., & Grieve, R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16447 · Cited by 4
Zhang, L., Zhu, Z., & Dong, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177900 · Cited by 3
van Walraven, C. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.200426 · Cited by 3
Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes
Solis‐Herrera, C., Cersósimo, E., & Triplitt, C. L. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0067 · Cited by 3
Person-Centered Medication Therapy for Diabetes in Older Adults: A Practical Review
Wilson, E. (2021) · Journal of Gerontological Nursing · doi:10.3928/00989134-20210908-02 · Cited by 3
CME: Metformin – Dos und Don’ts CME-Fragen
Slahor, L. (2021) · Praxis · doi:10.1024/1661-8157/a003774 · Cited by 3
Singa, T. A., Okechukwu, P. N., Amit, Z., Ibrahim, M. J., Капитонова, М. Ю., & Froemming, G. R. A. (2022) · Medicinal Plants - International Journal of Phytomedicines and Related Industries · doi:10.5958/0975-6892.2022.00044.2 · Cited by 3
Nazu, N. A., Wikström, K., Lamidi, M., Lindström, J., Tirkkonen, H., Rautiainen, P., & Laatikainen, T. K. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01889-3 · Cited by 3
“Monotherapy has been found to not be sufficient to maintain the glucose levels for most T2D patients because of the progressive nature of the disease [34].”
BackgroundXanthan gum-based nanocarriers for therapeutic delivery
Afnan, U., Sharma, K., Sehgal, R., & Kumar, V. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85656-0.00008-5 · Cited by 5
Schürmann, L., Bredehorst, M., González‐González, A. I., Muth, C., van der Wardt, V., Puzhko, S., & Haasenritter, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074788 · Cited by 3
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Metzendorf, M., Richter, B., & Hemmingsen, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368 · Cited by 3
Choxi, R., Roy, S., Stamatouli, A. M., Mayer, S., & Jovin, I. S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1756778 · Cited by 3
“weight, and cardiovascular mortality [34].”
An Overview of Hypoglycemic Modern Drugs
Chen, H., & Lu, Y. (2021) · Springer eBooks · doi:10.1007/978-981-15-8791-7_2 · Cited by 3
Gomes, G. J. N., Sartori, G. L., Sampaio, A. M., Pereira, L. M. V., Ueta, J. M., & de Oliveira, R. E. M. (2021) · Saúde em Redes · doi:10.18310/2446-4813.2021v7n1p217-227 · Cited by 5
Metadata
- Authors
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S.
- Affiliations
- MetroHealth (US)
- From The Johns Hopkins University School of Medicine; The Johns Hopkins University Bloomberg School of Public Health; and Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, and Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University; MetroHealth Medical Center; and Case Western Reserve University, Cleveland, Ohio.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 740-751
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2340898396
- Cited by
- 682
- References
- 66
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 60 · 2023: 68 · 2022: 80 · 2021: 90 · 2020: 89 · 2019: 71 · 2018: 68 · 2017: 56 · 2016: 11
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- Agency for Healthcare Research and Quality (290-2012-00007-I)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, monotherapy, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular mortality, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, genital mycotic infections, first-line therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.